Trevena Inc (TRVN) Receives Consensus Recommendation of “Buy” from Analysts

Trevena Inc (NASDAQ:TRVN) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $5.63.

Several analysts recently commented on the company. HC Wainwright reaffirmed a “hold” rating and set a $1.25 target price on shares of Trevena in a report on Thursday, March 14th. Zacks Investment Research raised Trevena from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Thursday, February 7th.

Trevena stock remained flat at $$1.50 during midday trading on Friday. The company had a trading volume of 1,180,697 shares, compared to its average volume of 1,184,776. The firm has a market capitalization of $138.53 million, a price-to-earnings ratio of -3.57 and a beta of 2.63. Trevena has a 12-month low of $0.38 and a 12-month high of $3.58. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.55 and a current ratio of 3.55.

Trevena (NASDAQ:TRVN) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $3.00 million. On average, sell-side analysts anticipate that Trevena will post -0.37 earnings per share for the current fiscal year.

In other Trevena news, CEO Maxine Gowen acquired 50,000 shares of the company’s stock in a transaction on Friday, February 1st. The shares were bought at an average cost of $1.02 per share, with a total value of $51,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leon O. Moulder, Jr. acquired 100,000 shares of the company’s stock in a transaction on Friday, February 1st. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $102,000.00. The disclosure for this purchase can be found here. 3.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Advisers LP lifted its position in shares of Trevena by 35.3% in the fourth quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 16,400 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of Trevena in the first quarter valued at approximately $283,000. Virtu Financial LLC purchased a new position in shares of Trevena in the fourth quarter valued at approximately $82,000. Geode Capital Management LLC lifted its position in shares of Trevena by 38.9% in the fourth quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 133,510 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Trevena by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock valued at $1,147,000 after acquiring an additional 80,437 shares in the last quarter. 21.78% of the stock is currently owned by institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Featured Story: Can individual investors take part in an IPO?

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.